Patent application number | Description | Published |
20080226550 | SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TUMORS - The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor. | 09-18-2008 |
20120269724 | COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS - The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited. | 10-25-2012 |
Patent application number | Description | Published |
20090075282 | ARTIFICIAL TISSUE CONSTRUCTS COMPRISING ALVEOLAR CELLS AND METHODS FOR USING THE SAME - The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers. | 03-19-2009 |
20120156670 | IN VITRO UROGENITAL CO-CULTURE MODELS - The invention is directed to co-culture systems comprising (i) rotating wall vessel (RWV)-cultured epithelial or differentiated tissue attached to microcarrier beads and (ii) the peripheral tissue equivalent (PTE) module of the MIMIC® system, and to methods of using the co-culture systems for assessing chemical or biological (bacterial or viral) insults. The system models mucosal exposure to chemicals, pathogens or antigen at various sites in the human body. The microcarrier and MIMIC® co-culture approach provides an in vitro co-culture model that simultaneously demonstrates mucosa-mediated antigen presentation and immunogenic responses. Models of the present invention can be used, for example, in assessments of disease pathogenesis and in pharmaceutical development, reproductive physiology, and immunological and toxicological evaluations. Models of the present invention can generate patient-specific localized mucosal immunology using primary cells, resembling the human physiological situation. | 06-21-2012 |
20140147482 | ARTIFICIAL TISSUE CONSTRUCTS COMPRISING ALVEOLAR CELLS AND METHODS FOR USING THE SAME - The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers. | 05-29-2014 |
Patent application number | Description | Published |
20110185282 | User-Interface-Integrated Asynchronous Validation for Objects - An asynchronous data validation mechanism integrated into a user interface by a binding engine is provided. Application object properties are bound to user interface data fields. The asynchronous validation mechanism communicates with a validator and with the object properties. Data input to a single field can be flagged with multiple validation errors. Multiple validation errors can also be associated to the object overall rather than being associated with particular properties of the object. Inconsistency between inputs to different data fields can result in a cross-property validation error. A single flag indicates whether the business object has any validation errors. Different validation errors may have different visualization types, and the business object may have validation errors of different data types, rather than being limited to strings. | 07-28-2011 |
20130067349 | EFFICIENTLY PROVIDING DATA FROM A VIRTUALIZED DATA SOURCE - Embodiments are directed to implementing data received from a virtualized data source and to efficiently providing data from a virtualized data source. In an embodiment, a computer system user interface (UI) sends a request for data elements to a data source. The computer system receives from the data source an indication that placeholder data is to be displayed while the requested data is retrieved and transmitted. The computer system then displays placeholder data in the UI for each of the requested data elements and dynamically adds the requested data elements to the displayed placeholder data as each data element is received from the data source. The data elements are dynamically added to the UI as they are received from the data source. | 03-14-2013 |
20130067372 | ALIAS SELECTION IN MULTIPLE- ALIASED ANIMATIONS - A computer system determines that various user interface (UI) elements are to be moved to a different position within the UI. The computer system initiates a first animation that creates first and second aliases for each UI element that is to be moved. The computer system then receives an input that interrupts the initiated first animation. The input indicates that at least one of the UI elements that is being moved during the first animation is to be moved to a different position. The computer system then determines which of the first and second aliases is optimal for use as a starting point for a second animation based on various visibility factors, and initiates a second animation at the determined optimal alias. The second animation uses the determined optimal alias as a starting point and a third, different alias as an end point. | 03-14-2013 |
20130106866 | LAYERING ANIMATION PROPERTIES IN HIGHER LEVEL ANIMATIONS | 05-02-2013 |
20130106885 | ALIASING OF LIVE ELEMENTS IN A USER INTERFACE | 05-02-2013 |
20130111382 | DATA COLLECTION INTERACTION USING CUSTOMIZED LAYOUTS | 05-02-2013 |
20130111413 | SEMANTIC NAVIGATION THROUGH OBJECT COLLECTIONS | 05-02-2013 |
20140285529 | VIRTUALIZED DATA PRESENTATION IN A CAROUSEL PANEL - Embodiments are directed to displaying data items in a carousel display panel and to efficiently presenting virtualized data in a carousel display panel. In one example, a computer system accesses a list of data items that include at least a first data item and a last data item which are to be displayed in a carousel display panel. The computer system displays the selected portion of data items in the carousel display panel and receives a user input indicating that the last data item in the list is to be displayed in the carousel display panel. The computer system then rotates the data items displayed in the carousel display panel to the last data item. The last data item is thus displayed, along with at least a portion of a second-to-last data item and the first data item in the list. | 09-25-2014 |
Patent application number | Description | Published |
20080238146 | FRONT RAIL HAVING CONTROLLED THICKNESS FOR ENERGY ABSORPTION - A frame rail for a vehicle that is provided between vehicle frame and the bumper of a vehicle that has a thickness that varies from the front end of the rail to the back end of the rail. The compressive strength of the rail increases from the front end of the rail to the back end of the rail. The rail is rectangular in shape and the thickness of the rail is continuously increased to improve progressive crush characteristics of the rail under an oblique loading. A rail may be provided by providing a tubular rail having a plurality of ring shaped segments that have incrementally increasing thickness. Alternatively, the rail may have a uniformly increasing thickness from the front end to the back end. | 10-02-2008 |
20100026053 | Dual Cell Body Side Rail for Automotive Vehicles - A body side rail construction for an automotive vehicle is formed in a dual cell configuration. A reversed C-shaped channel is welded to the closed section of the conventional roof side rail member to enable the body side rail member to be a smaller section that is less susceptible to buckling as the body side rail member transfers load to the front and rear corner pillars. The C-shaped cross-sectional configuration presents advantages for manufacturing as it can be shaped to provide the attaching brackets and horns for mounting the front header, roof bow, and rear header members to the body side rail without the addition of individual end items to serve this function. From a shipping density standpoint, this design gives maximum structure while maintaining good rack density that enables relatively straight parts to be nested together while still providing the increased section strength required for enhanced roof performance. | 02-04-2010 |
20100026054 | Moon Roof Frame Module for Reinforcement of Automotive Roof - A moon roof frame module is sized to span between the laterally spaced roof side rails of an automotive roof frame structure and is welded to the opposing roof side rails to be integrated into the roof frame structure. As a result, the moon roof assembly serves as a load path member to reinforce the automotive roof structure. The integrated moon roof frame module will receive roll over forces and increase the strength of the roof structure of an automotive vehicle. The moon roof frame module includes a U-shaped roof panel that is welded to the opposing roof side rails and provides a reinforcing cross member located forwardly of the moon roof opening. A second cross member positioned rearwardly of the moon roof opening increases rigidity of the reinforcing moon roof frame module. | 02-04-2010 |
20100237661 | VEHICLE BODY STRUCTURE - A vehicle body structure having improved roof support characteristics is provided. The structure includes a roof rail integral to an A-pillar and a support pillar. The structure further includes a cross member. The A-pillar includes an inner surface, an outer surface, and a wall therebetween. The roof rail extends downwardly at a front end of the roof rail and extends downwardly at a rear end of the roof rail. The roof rail is integral to a one piece hollow A-pillar at the front end of the roof rail. The support pillar also includes an inner surface, an outer surface, and a wall therebetween. The support pillar also includes a tubular lower section that extends upwardly from the rocker. The upper section of the support pillar is integral to the rear end of the roof rail. | 09-23-2010 |
20110233947 | Zero Stack-Up Telescopically Collapsible Energy Absorbing Rail and Bracket Assembly - An energy absorbing assembly for a vehicle that has a bumper and a frame. A receptacle is defined within the frame. A collapsible member is provided between the bumper and a recessed location spaced away from the bumper in the receptacle. The collapsible member may collapse at least partially into the receptacle in the event of a collision. | 09-29-2011 |
Patent application number | Description | Published |
20100129401 | Functional Influenza Virus Like Particles (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 05-27-2010 |
20100247574 | CHIMERIC NEWCASTLE DISEASE VIRUS VLPs - The present invention discloses and claims chimeric virus like particles (VLPs) that express and/or contains Newcastle disease matrix protein. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising chimeric VLPs of the inventions. The invention also includes methods of making and administrating chimeric VLPs to vertebrates, including methods of inducing immunity to infections. | 09-30-2010 |
20130295135 | FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 11-07-2013 |
20150374813 | FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 12-31-2015 |
Patent application number | Description | Published |
20080233150 | RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV. | 09-25-2008 |
20090017066 | NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN - The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza. | 01-15-2009 |
20120207786 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 08-16-2012 |
20140193447 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 07-10-2014 |
20140234372 | NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN - The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza. | 08-21-2014 |
Patent application number | Description | Published |
20100104652 | Use of advanced nanomaterials for increasing sepecific cell functions - Disclosed herein are methodologies and compositions for enhancing cellular functions, which can be used in a variety of biological applications. | 04-29-2010 |
20100285138 | COMPOSITIONS COMPRISING NANOPARTICLES AND APOPTOTIC AGENTS AND METHODS OF USE - Compositions comprising nanoparticles, such as silver or gold nanoparticles or carbon nanotubes (CNTs), and apoptotic agents are described. The nanoparticles can significantly enhance the cancer chemotherapeutic effects of the apoptotic agents. In particular, a highly increased anti-tumor activity has been demonstrated for the combination of etoposide and CNTs against HeLa cells compared to the administration of either etoposide alone or nanoparticles alone. Data provided by flow cytometry, Caspase 3 and other methods, suggest a strong interaction between the nanoparticles and the cellular structure, which can result in the improved effectiveness of chemotherapeutic agents. These findings provide potential new cancer therapies by carefully selecting the right combination of cytostatic drugs and nanostructural materials which synergistically provide significantly greater curative rates. | 11-11-2010 |
20160101126 | COMPOSITIONS COMPRISING NANOPARTICLES AND APOPTOTIC AGENTS AND METHODS OF USE - Compositions comprising nanoparticles, such as silver or gold nanoparticles or carbon nanotubes (CNTs), and apoptotic agents are described. The nanoparticles can significantly enhance the cancer chemotherapeutic effects of the apoptotic agents. In particular, a highly increased anti-tumor activity has been demonstrated for the combination of etoposide and CNTs against HeLa cells compared to the administration of either etoposide alone or nanoparticles alone. Data provided by flow cytometry, Caspase 3 and other methods, suggest a strong interaction between the nanoparticles and the cellular structure, which can result in the improved effectiveness of chemotherapeutic agents. These findings provide potential new cancer therapies by carefully selecting the right combination of cytostatic drugs and nanostructural materials which synergistically provide significantly greater curative rates. | 04-14-2016 |
Patent application number | Description | Published |
20080318870 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 12-25-2008 |
20100160276 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 06-24-2010 |
20120238537 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 09-20-2012 |
20120302525 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 11-29-2012 |
20130029958 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 01-31-2013 |
20130190283 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 07-25-2013 |
20130252931 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 09-26-2013 |
20140038932 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 02-06-2014 |
20150094261 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 04-02-2015 |
20160022700 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 01-28-2016 |
Patent application number | Description | Published |
20130146355 | ENVIRONMENTALLY SEALED CABLE BREAKOUT ASSEMBLIES - A cable breakout assembly is provided, including a feeder cable, a breakout structure having a first end threadedly engaged with a cable nut having a single-port cable gland through which the feeder cable extends, a central conduit which houses the sections of the feeder cable passing there through, and an opposed second end threadedly engaged with a cable nut having a multi-port cable gland, whose number of ports corresponds to the number of splices of the feeder cable. A plurality of environmentally sealed, flexible conduits are provided, each having a first end that interfaces with and extends from a respective port of the multi-port gland, and a second end adapted to interface with an external device, wherein each flexible conduit houses a respective spliced section of the feeder cable therein. | 06-13-2013 |
20150055926 | ENVIRONMENTALLY SEALED CABLE BREAKOUT ASSEMBLIES - A cable breakout assembly is provided, including a feeder cable, a breakout structure having a first end threadedly engaged with a cable nut having a single-port cable gland through which the feeder cable extends, a central conduit which houses the sections of the feeder cable passing there through, and an opposed second end threadedly engaged with a cable nut having a multi-port cable gland, whose number of ports corresponds to the number of splices of the feeder cable. A plurality of environmentally sealed, flexible conduits are provided, each having a first end that interfaces with and extends from a respective port of the multi-port gland, and a second end adapted to interface with an external device, wherein each flexible conduit houses a respective spliced section of the feeder cable therein. | 02-26-2015 |
20160049782 | ENVIRONMENTALLY SEALED CABLE BREAKOUT ASSEMBLIES - A cable breakout assembly is provided, including a feeder cable, a breakout structure having a first end threadedly engaged with a cable nut having a single-port cable gland through which the feeder cable extends, a central conduit which houses the sections of the feeder cable passing there through, and an opposed second end threadedly engaged with a cable nut having a multi-port cable gland, whose number of ports corresponds to the number of splices of the feeder cable. A plurality of environmentally sealed, flexible conduits are provided, each having a first end that interfaces with and extends from a respective port of the multi-port gland, and a second end adapted to interface with an external device, wherein each flexible conduit houses a respective spliced section of the feeder cable therein. | 02-18-2016 |
Patent application number | Description | Published |
20130112767 | Fuel Injector With Needle Control System That Includes F, A, Z and E Orifices - A common rail fuel injector includes a needle valve member that moves to open and close nozzle outlets for a fuel injection event responsive to pressure in a needle control chamber. Between injection events, the needle control chamber is fluidly connected to the fuel inlet by a first pathway that includes a Z orifice, and fluidly connected to the fuel inlet by a second pathway that includes an F orifice, an intermediate chamber and an A orifice. During an injection event, the needle control chamber is fluidly connected to a drain outlet by a third pathway that includes the A orifice, the intermediate chamber an E orifice and a buffer chamber, which may assist in avoiding cavitation erosion in a sensitive area associated with a flat control valve seat. Different performance characteristics are achieved by adjusting the sizes of the respective of F, A, Z and E orifices. | 05-09-2013 |
20130133621 | Thrust Lubrication Strategy For Roller Lifters Of A Common Rail Fuel Pump - A common rail fuel pump includes a cam shaft with at least one cam rotatably supported in a pump housing. A plurality of tappet assemblies are each reciprocatingly movable in the pump housing, and include an axle pin mounted in a tappet, and a roller mounted in contact for rotation about the axle pin. Each end of the roller includes a plurality of non-contiguous planar thrust surfaces separated by lubrication grooves. A lubrication pathway for the roller includes in sequence a lubrication passage that opens to a roller bearing surface, movement along the roller bearing surface into the lubrication grooves, and then between the planar thrust surface of the roller and a counterpart thrust face of the tappet responsive to rotation of the roller on the cam shaft. | 05-30-2013 |
Patent application number | Description | Published |
20100166669 | METHODS OF IMAGING INFLAMMATION IN PANCREATIC ISLETS - Described are non-invasive methods for imaging pancreatic inflammation in living mammals using Magnetic Nanoparticle Probes (MNPs). | 07-01-2010 |
20110152501 | Activatable Imaging Probes - The invention relates to activatable imaging probes that include a chromophore attachment moiety and a plurality of chromophores, such as near-infrared chromophores, chemically linked to the chromophore attachment moiety so that upon activation of the imaging probe by interaction with a target molecule the optical properties of the plurality of chromophores are altered. The probe optionally includes protective chains or chromophore spacers, or both. Also disclosed are methods of using the imaging probes for in vivo and in vitro optical imaging. | 06-23-2011 |
20120150043 | SYSTEMS AND METHODS FOR GENERATING FLUORESCENT LIGHT IMAGES - An imaging system divides image pixels intensities by exposure time to generate image data in units of intensity per time. The imaging system divides a fluorescent light image in intensity per time units by an excitation light image in intensity per time units to provide a quantitative corrected fluorescent light image that is generally invariant to position of an imaging instrument relative to a biological tissue being imaged. | 06-14-2012 |
20160030022 | Optical Biopsy Needle and Endoscope System - An interventional optical molecular imaging system and method are provided for use with a biopsy introducer needle. The system includes an imaging tool configured to slide coaxially through the biopsy introducer needle toward a tip of the biopsy introducer needle. The system also includes a laser illumination source coupled to the imaging tool, a camera configured to capture images from the imaging tool, and a computer coupled to the camera and the laser illumination source. The computer includes a processor configured to activate the laser illumination source to emit light through a tip of the imaging tool, collect imaging data from the camera after activating the laser illumination source, analyze the imaging data to determine a fluorescence measurement at the tip of the imaging tool, and display an indication of the fluorescence measurement. | 02-04-2016 |
20160033414 | OPTICAL PATHOLOGY SYSTEMS AND METHODS - An optical imaging method for analyzing an ex vivo tissue sample of a subject is provided. The method includes obtaining the ex vivo tissue sample, preparing the ex vivo tissue sample onto a sample receptacle of an optical imaging system, and emitting excitation light toward the ex vivo tissue sample. The method also includes acquiring imaging data of light emitted by the ex vivo tissue sample in response to the excitation light, analyzing the imaging data to determine whether the ex vivo tissue sample contains pathologic tissue, and generating an output indicating to an operator whether the ex vivo tissue sample contains pathologic tissue. | 02-04-2016 |